The Anticipated Impact of the Australian Cervical HPV DNA Screening Program on Detection of Adenocarcinoma in situ and the Unexpected Impacts of HPV DNA Testing on Postmenopausal Women

Publication date: September–October 2019Source: Journal of the American Society of Cytopathology, Volume 8, Issue 5Author(s): Bryan Knight
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research

Related Links:

Endoscopic surveillance is currently recommended in patients with Barrett's esophagus (BE) to detect prevalent and incident dysplasia/esophageal adenocarcinoma. This strategy is underpinned by the concepts that (1) dysplasia can be treated endoscopically to prevent early gastric cancer (EAC),1 and (2) early-stage EAC (without symptomatic dysphagia and muscularis propria invasion) can be successfully treated (endoscopically) with excellent long-term survival.2
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Tags: Original article Source Type: research
Authors: Zeng X, Liu Q, Yang Y, Jia W, Li S, He D, Ma R Abstract Placenta-specific protein 8 (PLAC8) is a conserved protein with a molecular weight of 12.5 kDa. The specific function of this protein has not been fully elucidated, however, PLAC8 has been found to play an important tumor regulatory role in certain types of cancer, including colon, pancreatic and liver cancer. PLAC8 also participates in the regulation of the cell cycle, autophagy, epithelial-mesenchymal transition and other cellular functions, indicating its potential as a molecular target worth further investigation. The present study investigated th...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
As a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib was approved by the US Food and Drug Administration for treatment of advanced non-small cell carcinoma with sensitizing EGFR mutations. Gefitinib is known to have adverse effects, which may necessitate dose reduction or even change to alternative preparation of epidermal growth factor receptor-tyrosine kinase inhibitor. There has been concern on dose reduction resulting in reduced dose gefitinib, especially on its efficacy. This was a retrospective single-center cohort study conducted in Queen Mary Hospital in Hong Kong that include...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
We present unusual treatment outcome in a 59-year-old male diagnosed with metastatic lung adenocarcinoma with a very good response to ruxolitinib as monotherapy. In June 2017, this patient was diagnosed with myeloproliferative neoplasm – Janus-associated kinases 2 positive – and in December 2017 ruxolitinib therapy was started. At the same time, patient was diagnosed with lung adenocarcinoma in the left lower lobe with positive anaplastic lymphoma kinase mutation and with right lower lobe metastasis. Because of partial regression of tumor size noted on the computed tomography (CT) scans during tumor investigati...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
We report the case of a 73-year-old patient with advanced lung adenocarcinoma who developed HPD following treatment with a unique dose of atezolizumab for a skin metastasis that was refractory to chemotherapy and radiotherapy. Potential clinical biomarkers related to HPD to ICIs are reviewed.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Authors: Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E Abstract [This corrects the article DOI: 10.18632/oncotarget.21109.]. PMID: 31620248 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Osther K, Förnvik K, Liljedahl E, Salford LG, Redebrandt HN Abstract Purpose: The complement system has recently sparked more interest in cancer research. The classical pathway is initiated by activation of the C1 complex, which irreversibly can be bound to and inhibited by C1-INH. We have previously shown that C1-INH is upregulated in human glioblastoma (astrocytoma grade IV) on both gene and protein level. We here examine whether the complement system seems to play a role also in pancreatic cancer. Technique and results: We performed an expression analysis of complement associated genes in 36 pa...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 16 October 2019Source: Life SciencesAuthor(s): Ahmed Hammad, Zhao-Hong Zheng, Yang Gao, Akhileshwar Namani, Hong-Fei Shi, Xiuwen TangAbstractAimsColorectal cancer (CRC) is the third most common cancer worldwide. Nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of many cytoprotective genes, plays a protective role in carcinogenesis. Recent studies have identified a specific gene-expression signature regulated by the Nrf2 pathway in lung adenocarcinoma and head-and-neck squamous cell cancer. However, the roles of Nrf2 in the development of colitis-associated colorectal...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionEven small polyps may become poorly differentiated adenocarcinoma with invasion, so close follow-up or endoscopic resection are recommended as well as eradication of Helico Pylori infection when appropriate.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionsThe efficacy of crizotinib in patients with advanced NSCLC is related to the number of metastatic organs, age and timing of treatment. The use of crizotinib is prone to intracranial progression, and progression of simple brain metastases is not an indication that crizotinib is discontinued. Patients will continue to benefit from combination of local radiotherapy.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Adenocarcinoma | Australia Health | Cytology | Women